Login to Your Account

Financings Roundup

PTC ‘Pax’ cash coffers, Macrogenics, too: $109M each in priced offerings

By Randy Osborne
Staff Writer

Friday, February 14, 2014
Though winter storm Pax put the freeze on air and ground traffic in the Northeast U.S. after ravaging the South, biotech funders seemed to feel little of the chill, with PTC Therapeutics Inc. and Macrogenics Inc. pricing public offerings for $109.7 million and $109.5 million, respectively.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription